{"entity":{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","aka":[],"tldr":"Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.","summary":"Lipika Goyal was principal investigator of FOENIX-CCA2, which won futibatinib approval for FGFR2 fusion-positive cholangiocarcinoma, and used serial ctDNA to describe the polyclonal FGFR2 kinase domain mutations that drive acquired resistance to FGFR inhibitors. She directs GI oncology at Stanford and leads trials of next-generation FGFR inhibitors.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma"}],"tags":["biliary","fgfr2","targeted-therapy"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["kinase-inhibitors","liquid-biopsy"],"targets":["fgfr2"],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["foenix-cca2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Medicine and Director of Gastrointestinal Oncology, Stanford Cancer Institute","institutionId":"stanford","specialisms":["Cholangiocarcinoma","FGFR2-targeted therapy","Acquired resistance","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma"}],"papers":[{"title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma (FOENIX-CCA2)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2206834"},{"title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.CD-16-1000"}],"orcid":"0000-0002-9777-6221"},"route":"/people/lipika-goyal/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"institution":[{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/"}],"trial":[{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/"}]}}